Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Side-by-side look at the strengths and weaknesses of zero-based budgeting and envelope systems to help you decide which suits your goals.
28,655 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Stocks rise on May 7, 2026 as AI-driven demand powers gains in the S&P 500 and SPY. Traders weigh earnings catalysts ...
Over a five-year span ending May 2026, SPHQ beat JQUA by about 5 percentage points despite a sharper pullback in 2022...
Bitwise argues that investors have not fully priced Hyperliquid's expansion into a multi-asset platform and the value...
A 65-year-old couple with $2.7 million in retirement assets faces a $48,000 annual drain from a Sonoma vineyard. The ...
May payrolls came in at 172,000, keeping the Fed on hold for higher-for-longer rates. Bitcoin slid as borrowing costs...
Oil sits near $90 per barrel on June 12, 2026, with Brent guiding the market. Traders weigh supply discipline, demand...
Oil price swings are back in 2026, prompting a closer look at the best energy ETFs for volatility. This piece breaks ...
A brutal four-session selloff in Korea’s chip sector erased roughly $900 billion in market value, even as analysts in...
Two sector income ETFs are delivering yields well above the S&P 500 as investors price in a possible recession. The g...
Tom Lee of Fundstrat says July could lift U.S. stocks as valuations normalize after June volatility, supported by eas...
Investors chase steady cash flow as Nasdaq exposure persists. The Invesco QQQ Income Advantage ETF delivers monthly p...